UCART19: Developed by Cellectis, UCART19 is an allogeneic CAR-T therapy targeting CD19, a common antigen in B-cell malignancies such as ALL and B-cell lymphoma. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.